CA2800203C - Morpholinopyrimidines et leur utilisation en therapie - Google Patents
Morpholinopyrimidines et leur utilisation en therapie Download PDFInfo
- Publication number
- CA2800203C CA2800203C CA2800203A CA2800203A CA2800203C CA 2800203 C CA2800203 C CA 2800203C CA 2800203 A CA2800203 A CA 2800203A CA 2800203 A CA2800203 A CA 2800203A CA 2800203 C CA2800203 C CA 2800203C
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- pyrimidin
- methylmorpholin
- methylsulfonimidoyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne les composés pyrimidinyle de formule (I), où R2 est (1) ou des sels pharmaceutiquement acceptables de ceux-ci, des processus pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en thérapie. .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35371310P | 2010-06-11 | 2010-06-11 | |
US61/353,713 | 2010-06-11 | ||
PCT/GB2011/051074 WO2011154737A1 (fr) | 2010-06-11 | 2011-06-09 | Morpholinopyrimidines et leur utilisation en thérapie |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2800203A1 CA2800203A1 (fr) | 2011-12-15 |
CA2800203C true CA2800203C (fr) | 2019-01-22 |
Family
ID=44168987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2800203A Active CA2800203C (fr) | 2010-06-11 | 2011-06-09 | Morpholinopyrimidines et leur utilisation en therapie |
Country Status (38)
Country | Link |
---|---|
US (5) | US8252802B2 (fr) |
EP (1) | EP2579877B1 (fr) |
JP (1) | JP5721821B2 (fr) |
KR (1) | KR101820996B1 (fr) |
CN (1) | CN103068391B (fr) |
AR (1) | AR081859A1 (fr) |
AU (1) | AU2011263491B2 (fr) |
BR (1) | BR112012031561B1 (fr) |
CA (1) | CA2800203C (fr) |
CL (1) | CL2012003503A1 (fr) |
CO (1) | CO6640270A2 (fr) |
CR (1) | CR20120628A (fr) |
CU (1) | CU24109B1 (fr) |
DK (1) | DK2579877T3 (fr) |
DO (1) | DOP2012000310A (fr) |
EA (1) | EA022087B1 (fr) |
EC (1) | ECSP12012334A (fr) |
ES (1) | ES2514325T3 (fr) |
GT (1) | GT201200334A (fr) |
HK (1) | HK1182019A1 (fr) |
HR (1) | HRP20140953T1 (fr) |
MX (1) | MX2012014477A (fr) |
MY (1) | MY158193A (fr) |
NI (1) | NI201200184A (fr) |
NZ (1) | NZ604480A (fr) |
PE (1) | PE20130306A1 (fr) |
PL (1) | PL2579877T3 (fr) |
PT (1) | PT2579877E (fr) |
RS (1) | RS53566B1 (fr) |
SA (1) | SA111320519B1 (fr) |
SG (1) | SG185711A1 (fr) |
SI (1) | SI2579877T1 (fr) |
SM (1) | SMT201400146B (fr) |
TW (1) | TWI526208B (fr) |
UA (1) | UA109010C2 (fr) |
UY (1) | UY33440A (fr) |
WO (1) | WO2011154737A1 (fr) |
ZA (1) | ZA201300255B (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
CA3000684A1 (fr) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Methode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr |
WO2018029117A1 (fr) * | 2016-08-10 | 2018-02-15 | Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) | Nouveaux inhibiteurs d'atr destinés à être utilisés dans le traitement du cancer |
JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
WO2018153969A1 (fr) | 2017-02-24 | 2018-08-30 | Bayer Aktiengesellschaft | Combinaison d'inhibiteurs de kinase atr et de sel de radium-223 |
WO2018153972A1 (fr) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combinaison d'inhibiteurs de kinase atr et d'anti-androgènes |
WO2018206547A1 (fr) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combinaison d'inhibiteurs de bub1 et d'atr |
EP3630116B1 (fr) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Inhibiteurs de la kinase atr à base de tétrahydropyrido[4,3-d]pyrimidine |
CN111867590B (zh) | 2017-07-13 | 2023-11-17 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
US11690911B2 (en) | 2017-08-04 | 2023-07-04 | Bayer Aktiengesellschaft | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors |
WO2019036641A1 (fr) * | 2017-08-17 | 2019-02-21 | Board Of Regents, The University Of Texas System | Inhibiteurs hétérocycliques de la kinase atr |
CN111655688B (zh) * | 2017-09-08 | 2023-09-29 | 蓝谷制药有限责任公司 | 经取代的吡咯并吡啶类化合物作为atr抑制剂 |
EP3461480A1 (fr) | 2017-09-27 | 2019-04-03 | Onxeo | Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer |
US11712440B2 (en) | 2017-12-08 | 2023-08-01 | Bayer Aktiengesellschaft | Predictive markers for ATR kinase inhibitors |
GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
JP7290651B2 (ja) * | 2018-02-07 | 2023-06-13 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Atr阻害剤及びその応用 |
WO2019178590A1 (fr) | 2018-03-16 | 2019-09-19 | Board Of Regents, The University Of Texas System | Inhibiteurs hétérocycliques de la kinase atr |
EP3866805A1 (fr) | 2018-10-16 | 2021-08-25 | Bayer Aktiengesellschaft | Combinaison d'inhibiteurs de kinase atr avec des composés de 2,3-dihydro-imidazo[1,2-c]quinazoline |
CA3122182A1 (fr) * | 2018-12-18 | 2020-06-25 | Astrazeneca Ab | Methode et formes intermediaires pharmaceutiques |
SG11202111402PA (en) | 2019-05-14 | 2021-11-29 | Nuvation Bio Inc | Anti-cancer nuclear hormone receptor-targeting compounds |
GB201908536D0 (en) * | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
CN112142744A (zh) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
EP4011881A4 (fr) * | 2019-08-06 | 2023-08-09 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Forme cristalline d'un inhibiteur d'atr et son utilisation |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CA3159376A1 (fr) * | 2019-11-21 | 2021-05-27 | Jiangsu Hengrui Medicine Co., Ltd. | Derive pyrazolo-heteroaryl, son procede de preparation et son utilisation medicale |
CN112939966B (zh) * | 2019-12-10 | 2023-03-24 | 武汉光谷亚太医药研究院有限公司 | 嘧啶衍生物、其制备及应用 |
TW202140474A (zh) * | 2020-01-17 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用 |
US20240150333A1 (en) * | 2020-03-20 | 2024-05-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Taf1 inhibitors |
EP4149455A1 (fr) | 2020-05-11 | 2023-03-22 | Astrazeneca AB | Inhibiteurs d'atr pour le traitement du cancer |
KR20230012586A (ko) * | 2020-05-29 | 2023-01-26 | 썬전 링팡 바이오테크 컴퍼니 리미티드 | 플루오로 피롤로 피리딘계 화합물 및 이의 용도 |
CN111646985A (zh) * | 2020-06-01 | 2020-09-11 | 江苏集萃分子工程研究院有限公司 | 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法 |
AU2021298251A1 (en) | 2020-06-24 | 2023-02-02 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and ATR inhibitor |
KR20230039675A (ko) * | 2020-07-13 | 2023-03-21 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Atr 키나제 억제제로 사용되는 피라졸로피리미딘 화합물 |
US20230399302A1 (en) * | 2020-10-29 | 2023-12-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Process for the preparation of heteroaryl-substituted sulfur(vi) compounds |
TW202304457A (zh) | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 配製物 |
BR112023019420A2 (pt) | 2021-03-23 | 2023-10-24 | Nuvation Bio Inc | Compostos de direcionamento ao receptor de hormônio nuclear anticâncer |
KR20230162030A (ko) | 2021-03-26 | 2023-11-28 | 아스트라제네카 아베 | 흑색종의 병용 치료법 |
IT202100021863A1 (it) * | 2021-08-13 | 2023-02-13 | Univ Degli Studi Milano | Morfolino pirimidine per l’uso nella prevenzione e/o nel trattamento di stati di ipereccitabilità neuronale |
WO2023039573A1 (fr) * | 2021-09-10 | 2023-03-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Composés pour la dégradation ciblée de taf1 |
CN116283960A (zh) * | 2021-12-21 | 2023-06-23 | 上海安诺达生物科技有限公司 | 取代的稠杂环化合物及其制备方法与应用 |
WO2023122723A1 (fr) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels et procédés de diagnostic et de traitement du cancer du poumon |
WO2023126823A1 (fr) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Association d'un conjugué anticorps-médicament et d'un inhibiteur d'atr |
TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
WO2023242302A1 (fr) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Polythérapie pour le traitement du cancer |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
EP0961780B1 (fr) | 1997-02-12 | 2007-04-11 | Electrophoretics Limited | Proteines-marqueurs pour le cancer du poumon et utilisation de ces dernieres |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
KR20080015482A (ko) | 1999-02-10 | 2008-02-19 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
US7173038B1 (en) | 1999-11-05 | 2007-02-06 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
WO2001060814A2 (fr) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole |
WO2001083456A1 (fr) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'heteroaryle condenses |
CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
DK1335906T3 (da) | 2000-11-10 | 2007-02-05 | Hoffmann La Roche | Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander |
EP2316831B1 (fr) | 2002-11-21 | 2013-03-06 | Novartis AG | Dérivés de 2-(morpholin-4-yl)pyrimidine comme inhibiteurs de Phosphotidylinositol (PI) 3-kinase pour le traitement de cancers. |
CA2527079A1 (fr) | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Composes heterocycliques permettant de prevenir et de traiter des troubles associes a une perte osseuse excessive |
GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2007084413A2 (fr) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Procedes de traitement de l’hepatite c |
US7696202B2 (en) | 2004-11-10 | 2010-04-13 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
WO2006124874A2 (fr) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibiteurs de la b-raf kinase |
TW200720256A (en) | 2005-05-13 | 2007-06-01 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
ES2473341T3 (es) | 2005-05-20 | 2014-07-04 | Methylgene Inc | Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF |
DE102005024494A1 (de) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
RU2386630C2 (ru) * | 2005-07-01 | 2010-04-20 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы |
WO2007013691A1 (fr) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Composé spiro-cyclique |
RU2008112313A (ru) | 2005-09-01 | 2009-10-10 | Эррэй Биофарма Инк. (Us) | Соединения ингибиторы raf и способы их применения |
JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
JP4531027B2 (ja) | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
SG151327A1 (en) | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
ES2535854T3 (es) | 2005-09-30 | 2015-05-18 | Miikana Therapeutics, Inc. | Compuestos de pirazol sustituidos |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
PT1945631E (pt) | 2005-10-28 | 2012-10-15 | Astrazeneca Ab | Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro |
EP1970375A4 (fr) | 2005-11-29 | 2010-06-02 | Toray Industries | Derive d'arylmethylene uree et utilisation de celui-ci |
GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525083D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
US20110034454A1 (en) * | 2006-01-11 | 2011-02-10 | Allan Paul Dishington | Morpholino pyrimidine derivatives and their use in therapy |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
BRPI0706747A2 (pt) | 2006-01-30 | 2011-04-05 | Exelixis Inc | 4-aril-2-amino-pirimidinas ou 4-aril-2-aminoalquil-pirimidinas como moduladores jak-2 e composições farmacêuticas que os contenham |
WO2007105023A1 (fr) | 2006-03-15 | 2007-09-20 | Csir | Modulation de l'activite phosphoryl transferase de la glutamine synthetase |
JP5243696B2 (ja) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
WO2007114323A1 (fr) | 2006-04-04 | 2007-10-11 | Taisho Pharmaceutical Co., Ltd. | Composé d'aminopyrrolidine |
CA2648809A1 (fr) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazoles et methodes d'inhibition de cdc7 |
WO2007126043A1 (fr) | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | Utilisation en tant que medicaments de derives d'un acide carboxylique porteurs de cycles thiazole |
GB0610909D0 (en) | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
US20090325957A1 (en) | 2006-08-24 | 2009-12-31 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
KR101435231B1 (ko) | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
EP2084159A1 (fr) * | 2006-10-16 | 2009-08-05 | GPC Biotech Inc. | Pyridoý2,3-d¨pyrimidines et utilisation de celles-ci en tant qu'inhibiteurs de kinases |
WO2008125833A1 (fr) | 2007-04-12 | 2008-10-23 | Piramed Limited | Composés pharmaceutiques |
US20100227858A1 (en) * | 2007-07-09 | 2010-09-09 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
KR20110082570A (ko) * | 2008-11-14 | 2011-07-19 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Hif 억제제로서 사용하기 위한 헤테로방향족 화합물 |
UY32351A (es) * | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
-
2011
- 2011-06-08 SA SA111320519A patent/SA111320519B1/ar unknown
- 2011-06-09 PT PT117254946T patent/PT2579877E/pt unknown
- 2011-06-09 AU AU2011263491A patent/AU2011263491B2/en active Active
- 2011-06-09 KR KR1020137000590A patent/KR101820996B1/ko active IP Right Grant
- 2011-06-09 PE PE2012002373A patent/PE20130306A1/es active IP Right Grant
- 2011-06-09 TW TW100120242A patent/TWI526208B/zh active
- 2011-06-09 RS RSP20140534 patent/RS53566B1/en unknown
- 2011-06-09 JP JP2013513758A patent/JP5721821B2/ja active Active
- 2011-06-09 UY UY0001033440A patent/UY33440A/es not_active Application Discontinuation
- 2011-06-09 SI SI201130280T patent/SI2579877T1/sl unknown
- 2011-06-09 EA EA201201680A patent/EA022087B1/ru not_active IP Right Cessation
- 2011-06-09 DK DK11725494.6T patent/DK2579877T3/da active
- 2011-06-09 CN CN201180039088.2A patent/CN103068391B/zh active Active
- 2011-06-09 EP EP11725494.6A patent/EP2579877B1/fr active Active
- 2011-06-09 SG SG2012086112A patent/SG185711A1/en unknown
- 2011-06-09 WO PCT/GB2011/051074 patent/WO2011154737A1/fr active Application Filing
- 2011-06-09 MX MX2012014477A patent/MX2012014477A/es active IP Right Grant
- 2011-06-09 ES ES11725494.6T patent/ES2514325T3/es active Active
- 2011-06-09 PL PL11725494T patent/PL2579877T3/pl unknown
- 2011-06-09 US US13/156,684 patent/US8252802B2/en active Active
- 2011-06-09 CA CA2800203A patent/CA2800203C/fr active Active
- 2011-06-09 BR BR112012031561A patent/BR112012031561B1/pt active IP Right Grant
- 2011-06-09 MY MYPI2012701121A patent/MY158193A/en unknown
- 2011-06-09 NZ NZ604480A patent/NZ604480A/en unknown
- 2011-06-10 AR ARP110102022A patent/AR081859A1/es active IP Right Grant
- 2011-09-06 UA UAA201215028A patent/UA109010C2/en unknown
- 2011-09-06 CU CU20120169A patent/CU24109B1/es active IP Right Grant
-
2012
- 2012-07-02 US US13/540,057 patent/US8552004B2/en active Active
- 2012-12-11 CL CL2012003503A patent/CL2012003503A1/es unknown
- 2012-12-11 CR CR20120628A patent/CR20120628A/es unknown
- 2012-12-11 EC ECSP12012334 patent/ECSP12012334A/es unknown
- 2012-12-11 DO DO2012000310A patent/DOP2012000310A/es unknown
- 2012-12-11 GT GT201200334A patent/GT201200334A/es unknown
- 2012-12-11 NI NI201200184A patent/NI201200184A/es unknown
- 2012-12-11 CO CO12224297A patent/CO6640270A2/es active IP Right Grant
-
2013
- 2013-01-10 ZA ZA2013/00255A patent/ZA201300255B/en unknown
- 2013-08-12 HK HK13109418.0A patent/HK1182019A1/xx unknown
- 2013-09-18 US US14/030,134 patent/US8999997B2/en active Active
-
2014
- 2014-10-03 HR HRP20140953AT patent/HRP20140953T1/hr unknown
- 2014-10-09 SM SM201400146T patent/SMT201400146B/xx unknown
-
2015
- 2015-02-26 US US14/631,961 patent/US9155742B2/en active Active
- 2015-09-21 US US14/859,567 patent/US9421213B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2800203C (fr) | Morpholinopyrimidines et leur utilisation en therapie | |
AU2008273891B2 (en) | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K | |
US20110053923A1 (en) | Chemical compounds 610 | |
AU2008273892A1 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20160531 |